Sarcoma metastatic to the brain: a series of 15 cases.
METHODS
We report on 15 patients surgically treated for intraparenchymal brain metastases from sarcoma, including six osteosarcomas, five leiomyosarcomas, two malignant fibrous histiocytomas, and two alveolar soft-part sarcomas (ASPS).


RESULTS
Median survival after craniotomy was 9.3 months. Patients with a preoperative Karnofsky performance score of > 70 survived for 12.8 versus 5.3 months for those with a Karnofsky performance score < 70 (p=0.03). Patients with evidence of only lung metastases at the time of surgery (nine cases) survived 8.6 months, which was similar to the 10.4-month survival for patients with disease limited to the brain (p=0.1). The two patients with alveolar soft-part sarcomas are alive at 15 and 20 months after surgery.


CONCLUSIONS
We conclude that surgery is effective in treating selected patients with sarcoma metastatic to the brain and that patients with metastasis from ASPS may have a relatively good prognosis if they are surgically treated. The complete removal of all brain metastases and a Karnofsky performance score > 70 are associated with a favorable prognosis; the presence of concurrent lung metastases is not a contraindication to surgery.
Salvati
M
M
Department of Neurosurgery, Neurological Mediterranean Neuromed Institute, IRCCS, Pozzilli (IS), Italy.
Cervoni
L
L
Caruso
R
R
Gagliardi
F M
FM
Delfini
R
R
D000293:Adolescent; D000328:Adult; D001859:Bone Neoplasms / Q000473:pathology; D001932:Brain Neoplasms / Q000556:secondary* / Q000601:surgery*; D002648:Child; D005260:Female; D018219:Histiocytoma, Benign Fibrous / Q000556:secondary; D006801:Humans; D017567:Karnofsky Performance Status; D007890:Leiomyosarcoma / Q000556:secondary; D008297:Male; D008875:Middle Aged; D012516:Osteosarcoma / Q000556:secondary; D012509:Sarcoma / Q000556:secondary* / Q000601:surgery*; D018234:Sarcoma, Alveolar Soft Part / Q000556:secondary; D016896:Treatment Outcome